Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Sciences : Robin L. Washington Named "Financial Woman of the Year"

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2017 | 05:48pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Robin L. Washington, executive vice president and chief financial officer of Gilead Sciences, Inc., has been named the 2017 Financial Woman of the Year by the Financial Women of San Francisco (FWSF), a 400-member organization of professionals in finance and financial services. This award is the organization's highest honor (see also Financial Women of San Francisco).

At Gilead, Washington established the Women's Leadership Forum for the CFO organization, which helps female leaders develop their leadership skills and facilitates discussions with female leaders throughout the organization and broader business community. She is also the recipient of numerous awards and accolades, including being named one of Black Enterprise's "Most Powerful Women in Corporate America"; ranking sixth on the Wall Street Journal's 2014 list of top-performing CFOs on the S&P 500; being awarded the Distinguished Alumni Award from Pepperdine University's Graziadio School of Business and Management; as well as being honored with the 2017 Bay Area CFO of the Year Awards' Lifetime Achievement Award.

"I am passionate about ensuring the advancement of women in leadership roles and careers in finance. As a senior female leader, it is an honor and responsibility to support and encourage women along their career and life journeys in the same way that my mentors and sponsors have supported me," said Washington. "I am deeply honored to receive this award, and grateful to the Financial Women of San Francisco for their sustained commitment to helping women advance their careers."

Washington will deliver a keynote address at the 22nd annual Financial Woman of the Year luncheon on October 6, 2017, an annual event that provides funding for scholarships for Bay Area women pursuing careers in finance and financial services.

A certified public accountant, Washington joined Gilead in 2008 as senior vice president and CFO, overseeing the global finance and information technology organizations. She was promoted to executive vice president in 2014. Prior to this she held executive and management positions with major Bay Area technology companies. She is a member of the board of directors of Honeywell International, Salesforce.com and UCSF Benioff Children's Hospital Oakland. Washington holds a bachelor's degree in business administration from the University of Michigan and an MBA from Pepperdine University.

Last year's Financial Woman of the Year event raised a record $418,000 in corporate in-kind and cash contributions. All proceeds benefit the FWSF Scholarship Fund, which directly funds scholarships for women in the San Francisco Bay Area pursuing a career in finance or financial services. FWSF has awarded over $2 million in scholarships over the past 30 years to more than 200 Bay Area women.

The Financial Woman of the Year award and celebratory luncheon was established in 1996 to celebrate the 40th Anniversary of the organization. Past FWSF Presidents Leslie Miller and Shelly Porges created the Financial Woman of the Year event with a triple purpose: to raise funds for FWSF's scholarship program, to create greater awareness of the FWSF, and to celebrate and promote careers of the most senior women in finance. Since then it has provided a platform for high-achieving honorees to share their professional experience with others, inspiring them in their own careers and ambitions. Washington joins a distinguished list of previous honorees, including Debbie Messemer, managing partner of KPMG's Bay Area Market; Carrie Dolan, former chief financial officer (CFO) of Lending Club; Sarah Friar, CFO of Square, and Pat Yarrington, CFO of Chevron.

For more information about the Financial Woman of the Year program, scholarship programs or to become a sponsor, click here. About The Financial Women of San Francisco The Financial Women of San Francisco seeks to advance the success of women in finance and financial services and to be a source of insight and inspiration to financial women executives and managers throughout the Bay Area.

The organization's membership includes women in positions of influence within the financial services sector and women who hold senior level positions within non-finance companies, government agencies and the non-profit sector. Members include CEOs, CFOs, corporate treasurers, CPAs, attorneys, commercial and private bankers, investment advisors, fund managers, securities analysts, administrators, financial planners, consultants, recruiters and marketers.

For more information please visit http://financialwomensf.org/ or follow the Financial Women of San Francisco on Twitter @FinanceWomenSF, Facebook and LinkedIn. View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005168/en/

Keywords for this news article include: Technology, Finance and Investment, Investment and Finance, Financial Women of San Francisco.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
04/27 GILEAD SCIENCES : Robin L. Washington Named "Financial Woman of the Year"
04/27 GILEAD SCIENCES : to Present Clinical and Preclinical Data on Nonalcoholic Steat..
04/27 GILEAD SCIENCES : to Release First Quarter 2017 Financial Results on Tuesday, Ma..
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/26 GILEAD SCIENCES : Phase II study showed 99% HCV cure rates
04/21 GILEAD SCIENCES : Announces Scientific Presentations Demonstrating Efficacy of H..
04/21 GILEAD SCIENCES : Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Ste..
04/20 GILEAD SCIENCES : U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in..
04/20 GILEAD SCIENCES : Presents Data at the International Liver Congress™ 2017 ..
04/20 GILEAD SCIENCES : to Present Clinical and Preclinical Data on Nonalcoholic Steat..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/29 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 29, 2017
04/29 What's A Rating Worth? Not Much!
04/28 Is Bristol-Meyers Squibb A Good Long-Term Pick?
04/28 GILEAD SCIENCES : Low Expectations
04/27 BRISTOL-MYERS SQUIBB : Becoming An Increasingly Attractive Target
Advertisement
Financials ($)
Sales 2017 24 705 M
EBIT 2017 15 254 M
Net income 2017 10 151 M
Debt 2017 2 430 M
Yield 2017 3,11%
P/E ratio 2017 9,28
P/E ratio 2018 10,20
EV / Sales 2017 3,73x
EV / Sales 2018 4,09x
Capitalization 89 611 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,9 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-4.27%89 611
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
ACTELION LTD24.13%28 742
More Results